Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance

Abstract EN

Extramedullary disease (EMD) in multiple myeloma (MM) patients is an uncommon event and more attention was directed toward the feature of these patients.

Cytogenetic aberration is an important characteristic of MM and is associated with patients’ outcome.

In this study, we aimed to compare the cytogenetic abnormality of patients with and without extramedullary manifestation, and to analyze the clinical outcomes of novel agents in EMD patients.

We retrospectively investigated data from 41 MM patients.

Our analyses showed del(17p13) in 31% of EMD versus 13% of medullary disease (P=0.03) and amp(1q21) in 55% versus 32% (P=0.019).

No differences were shown in del(13q14) and t(4;14).

24/27 patients with EMD at diagnosis responded to the novel agents-containing regimens.

However, when relapsed, 70% of patients did not benefit from the sequential use of novel agents as salvage therapy.

In 14 patients who developed EMD at relapse phase, only 2 patients responded to novel agents therapy.

Median overall survival of patients with extramedullary manifestations was 30 months, in comparison to 104 months for patients without EMD (P=0.002).

Patients with extramedullary manifestation bore high incidence of poor cytogenetic aberration and novel agents resistance.